BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Survival in adults with acute myelogenous leukemia].

BACKGROUND: Acute myelogenous leukemia is the most common type of acute leukemia in adults.

The condition is lethal within a few months without treatment, but most young patients reach complete remission with chemotherapy.

MATERIAL AND METHODS: Survival data were retrieved from the Norwegian Registry for Acute Leukemias and Lymphoblastic Lymphomas for patients with acute myelogenous leukemia (aged from 16 to 60 years) who were registered in the period 1.1.2000-31.12.2005.

Patients with secondary acute myelogenous leukemia were classified as high-risk.

RESULTS AND INTERPRETATION: 4-year survival was 94.5% in acute promyelocytic leukemia, 77.7% in other low-risk acute myelogenous leukemia, 39.0% in standard risk patients and 29.1% in high-risk patients.

The increase is most probably due to an intensification of chemotherapy after remission and to the implementation of all-trans-retinoic acid in the treatment of promyelocytic leukemia.

[MeSH-major] Leukemia, Myeloid, Acute / mortality

[MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / mortality. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Norway / epidemiology. Risk Factors. Survival Rate

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Tidsskr Nor Laegeforen. 2008 Aug 14;128(15):1681-2; author reply 1682 [18704137.001]

(PMID = 18480864.001).

[ISSN] 0807-7096

[Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række

[ISO-abbreviation] Tidsskr. Nor. Laegeforen.

[Language] nor

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Norway

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.

Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML).

The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission.

Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P = .03).

Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation / mortality. Leukemia, Myeloid, Acute / mortality

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Autologous

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16443518.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U24-CA76518

[Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.

Autologous peripheral blood stem/progenitor cell transplantation (APBSCT) has been investigated as a potential therapeutic option to improve outcome in patients with acute myelogenous leukemia (AML).

However, its optimal role in treatment for adults in remission has not been clearly established.

We performed a retrospective analysis on 45 patients aged 21 to 73 years (median 51 years) with de novo AML who underwent APBSCT stratified by age, complete remission status, and cytogenetic risk.

We conclude that APBSCT is a reasonable and safe intensive consolidation for patients with AML who do not have a suitable HLA-matched donor.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy

[MeSH-minor] Adult. Age Factors. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Rate. Time Factors. Transplantation, Autologous

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19747639.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.

Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML).

To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory.

We evaluated the effect of CD34(+) cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1).

The high CD34(+) cell dose patients had better overall survival (5-year overall survival rate, 75% +/- 6% vs 52% +/- 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% +/- 6% vs 44% +/- 9%; P = .04).

CD34(+) cell dose was the only independent prognostic factor in overall survival and leukemia-free survival.

There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34(+) cell dose groups.

We confirmed that high CD34(+) cell dose favorably affects the outcomes in allogeneic BMT for AML.

The effort to attain a high CD34(+) cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1.

[MeSH-major] Antigens, CD34 / analysis. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Leukemia, Myeloid, Acute. Tissue Donors

[MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Leukocyte Count. Male. Middle Aged. Recurrence. Siblings. Transplantation, Homologous. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15682073.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.

Cytogenetic analysis at the time of diagnosis predicts outcome in patients with acute myelogenous leukemia (AML).

We treated patients with de novo AML and age less than 60 years first with etoposide, mitoxantrone, cytarabine, and G-CSF (EMA-G) to induce remission.

Patients in complete remission were assigned to treatment with chemotherapy alone if they had favorable risk cytogenetics defined as the identification of a core-binding factor translocation.

Of the 33 patients in remission, 5 year relapse-free survival (RFS) and overall survival (OS) was 46 and 38%, respectively.

Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Adult. Chromosome Aberrations / classification. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction / methods

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2008 Wiley-Liss, Inc.

[CommentIn] Am J Hematol. 2008 Nov;83(11):829-30 [18828158.001]

(PMID = 18756545.001).

[ISSN] 1096-8652

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of timed sequential chemotherapy in adult acute myelogenous leukemia.

Consecutive trials of timed sequential chemotherapy (TSC) have been conducted in adults with acute myelogenous leukemia.

Achieving complete remission is essential for prolonged disease-free survival and may affect long-term outcome.

TSC has led to higher rates of complete remission and has improved long-term outcomes.

This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Adult. Cell Cycle / drug effects. Clinical Trials as Topic. Drug Administration Schedule. Humans

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20425452.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 50

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.

Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of adult acute myelogenous leukemia (AML) patients, mainly with a normal karyotype.

In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese AML patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.

The detection rate of NPM1 mutations in 220 AML patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.

Eight patients were followed up after treatment, and five patients in hematologic remission continued to test negative for NPM1 mutations within 2-14 months of follow-up.

The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening AML, and for the quantitative analysis of minimal residual diseases.

[MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics

[MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. China / epidemiology. Female. Follow-Up Studies. Gene Dosage / genetics. Humans. Indicator Dilution Techniques. Male. Middle Aged. Mutation / genetics. Plasmids / genetics. Sensitivity and Specificity

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18726096.001).

[ISSN] 1432-0584

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.

Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy.

Assessment of remission and treatment decisions are based on cytological findings.

We analyzed the prognostic impact of cytogenetic remission status in 118 patients with abnormal karyotype who received induction chemotherapy.

Eighty-three patients achieved complete remission (CR) and 20 achieved partial remission.

Median survival (excluding patients with AML M3) of the CCR group was 37 months, as compared to 11 months in patients with persistence of abnormal karyotype (p < 0.0001).

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Remission Induction

[MeSH-minor] Adult. Aged. Female. Humans. Karyotyping. Male. Middle Aged. Prognosis. Translocation, Genetic

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19428106.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sacroiliitis as an initial manifestation of acute myelogenous leukemia.

We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML).

Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with Sacroiliitis.

Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis.

However, the sacroiliitis relapsed when the leukemia cells progressed thereafter.

The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient.

Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML.

No previous report has described sacroiliitis as the initial manifestation of de novo AML.

[MeSH-major] Leukemia, Myeloid, Acute. Sacroiliac Joint. Spondylitis, Ankylosing

[MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Blast Crisis / diagnosis. Blast Crisis / radiography. Blast Crisis / therapy. Bone Marrow Transplantation. Fatal Outcome. Female. Humans. Recurrence. Transplantation, Homologous

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17189223.001).

[ISSN] 0925-5710

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adrenal Cortex Hormones

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].

OBJECTIVE: To explore the prevalence and prognostic significance of JAK2V617F gene mutation in acute myelogenous leukemia M2 (AML-M2) patients.

RESULTS: Of 80 de novo AML-M2 patients, 6 at the time of first diagnosis and 1 at relapse were found to have JAK2V617F gene mutation (8.8%, 7/80).

Morphologically, the whole blood and bone marrow of the 7 AML-M2 patients with JAK2V617F gene mutation presented a picture of acute leukemia instead of myeloproliferative disorders.

Immunophenotypically, bone marrow samples showed myelogenous linage expression.

Complete remission was obtained in 4 of 5 AML-M2 patients with JAK2V617F mutation who received treatment, while one patient had no response to the treatment.

CONCLUSION: JAK2V617F gene mutation, as a type-1 mutation, might not be an initial event in the pathogenesis of acute myelogenous leukemia, and its presentation does not mean a poor prognosis in de novo AML patients.

[MeSH-major] Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Mutation

[MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Rate. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19799086.001).

[ISSN] 0253-3766

[Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]

[ISO-abbreviation] Zhonghua Zhong Liu Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).

: 7062 Background: The CLASSIC II trial has previously reported an independently confirmed overall remission rate of 46% (38% CR and 8% CRp) and 30- and 60-day mortality rates of 9.8% and 16.1%, respectively (Blood 112: 558, 2008).

We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).

METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.

Patients were followed for at least 6 months past remission (CR/CRp).

CONCLUSIONS: These data expand on the previously reported efficacy and safety data of single agent CLO in adult AML.

These results suggest that single agent CLO is an effective and tolerable treatment option for older adult patients with untreated AML and 1 or more unfavorable baseline prognostic factor(s).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961436.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Outcome of patients with acute myelogenous leukemia after second salvage therapy.

BACKGROUND: Although the prognosis is poor for patients with acute myelogenous leukemia (AML) who have disease recurrence after frontline therapy, this is a general reflection of first salvage therapies.

The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival.

METHODS: The records of 594 patients with AML undergoing second salvage therapy from 1980 until 2004 were reviewed.

Salvage therapy included allogeneic stem cell transplantation (SCT) in 74 patients, standard-dose cytosine arabinoside (ara-C) combinations in 30 patients, high-dose ara-C combinations in 171 patients, non-ara-C combinations in 73 patients, and Phase I-II single agents in 246 patients.

A multivariate analysis of prognostic factors for CR identified the following 6 independent adverse factors: first CR duration < 6 months; second CR duration < 6 months; salvage therapy not including allogeneic SCT; non-inversion 16 AML; platelet counts < 50 x 10(9)/L, and leukocytosis > 50 x 10(9)/L.

CONCLUSIONS: The current analysis established the outcome and prognostic factors associated with second salvage therapy in AML.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / therapy. Salvage Therapy. Stem Cell Transplantation. Transplantation, Homologous

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2005 American Cancer Society.

(PMID = 15973664.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.

The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy.

Adults with de novo AML received daunorubicin and cytosine arabinoside induction therapy.

Patients achieving complete remission received high dose ara-C (HIDAC) for three courses followed by low dose rIL-2 (Amgen), administered by continuous infusion (450,000 U/m(2)/day) for 10 weeks with intermittent boluses (500,000/U/m(2) over 2 hr) given in weekly intervals starting on Week 4.

Mononuclear cells from patients receiving rIL-2 exhibited enhanced cytolytic activity in vitro against cryopreserved autologous leukemia cells.

This study supports further investigation of immunotherapy in the post-intensive chemotherapy setting in the management of patients with AML.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy

[MeSH-minor] Acute Disease. Adult. Aged. Clinical Trials as Topic. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dose-Response Relationship, Drug. Fatigue / chemically induced. Feasibility Studies. Female. Fever / chemically induced. Follow-Up Studies. Humans. Interleukin-2 / administration & dosage. Interleukin-2 / genetics. Killer Cells, Natural / drug effects. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Remission Induction. Survival Analysis. T-Lymphocytes / drug effects. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2008 Wiley-Liss, Inc.

(PMID = 18756547.001).

[ISSN] 1096-8652

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA66996

[Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute myelogenous leukemia or myelodysplastic syndromes.

Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first untreated relapse at the time of transplantation.

These data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory myeloid leukemias.

[MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy

[MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15682071.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.

Considering that ring chromosomes are rare in acute myelogenous leukemia (AML), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality.

Here we report a case of a ring chromosome 18 abnormality in a patient with newly diagnosed AML with monocytic differentiation.

The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic remission for 120 days post transplant.

Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of AML (likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation.

[MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Ring Chromosomes

[MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Treatment Outcome

Genetic Alliance. consumer health - Chromosome 18.

Genetic Alliance. consumer health - Chromosome 18, Ring.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]

[Cites] Cytogenet Genome Res. 2008;121(3-4):149-73 [18758155.001]

[Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):20-9 [12203786.001]

[Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]

[Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]

[Cites] Cancer Genet Cytogenet. 1983 Jan;8(1):51-66 [6572548.001]

[Cites] Cancer Res. 1985 Jan;45(1):430-4 [3855285.001]

[Cites] Blood. 1987 Nov;70(5):1400-6 [3663939.001]

[Cites] Cancer Genet Cytogenet. 1988 Jun;32(2):157-68 [3163258.001]

[Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):244-9 [7522537.001]

[Cites] Cancer Genet Cytogenet. 1995 Jul 1;82(1):41-9 [7627933.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):76-8 [9973965.001]

[Cites] Hum Genet. 1999 Apr;104(4):315-25 [10369161.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]

[Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]

[Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):137-53 [11979548.001]

(PMID = 20649984.001).

[ISSN] 1756-8722

[Journal-full-title] Journal of hematology & oncology

[ISO-abbreviation] J Hematol Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

[Other-IDs] NLM/ PMC2917391

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.

Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials.

In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM.

These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]

[Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]

[Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]

[Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]

[Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]

[Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]

[Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]

[Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]

[Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]

[Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]

[Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]

[Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]

[Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]

[Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]

[Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]

[Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]

[Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]

[Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]

[Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]

[Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]

[Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]

[Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]

[Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]

[Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]

[Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]

(PMID = 18215779.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08

[Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute myelogenous leukemia with outpatient azacitidine.

BACKGROUND: Patients older than 55 years of age with acute myelogenous leukemia (AML) are less likely to achieve complete remission and more likely to experience toxicity with conventional induction chemotherapy than younger patients.

Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS).

At higher doses, azacitidine has activity in AML.

Patients with blast counts up to 29% were initially treated as MDS, but by WHO now meet criteria for AML.

CONCLUSIONS: Azacitidine administered in the outpatient setting can induce remission in AML.

[MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Azacitidine / administration & dosage. Leukemia, Myeloid / drug therapy. Outpatients

[MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Retrospective Studies

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. AZACITIDINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2006 American Cancer Society

(PMID = 16967444.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; M801H13NRU / Azacitidine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).

The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described.

The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years).

We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.

[MeSH-major] Leukemia, Myeloid, Acute / diagnosis

[MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Leuk Lymphoma. 2007 Jan;48(1):3-4 [17325840.001]

(PMID = 17325849.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia.

Patient 1 is a 32-year-old woman with acute myelogenous leukemia (AML)-M5a who underwent CBT.

Patient 2 is a 42-year-old man with AML-M4 who underwent CBT.

[MeSH-major] Autoimmune Diseases / blood. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute. Thyrotoxicosis / blood

[MeSH-minor] Adult. Autoantibodies / blood. Autoantibodies / immunology. Female. Humans. Iodide Peroxidase / immunology. Male. Remission, Spontaneous. Thyroxine / blood. Thyroxine / immunology. Transplantation, Homologous. Triiodothyronine / blood. Triiodothyronine / immunology

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

Hazardous Substances Data Bank. LEVOTHYROXINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16757437.001).

[ISSN] 0925-5710

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Autoantibodies; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.

PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.

Such patients might benefit from additional therapy in complete remission (CR).

Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.

We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.

Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics.

CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]

[Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]

[Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]

[Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]

[Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]

[Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]

[Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]

[Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]

[Cites] Am J Clin Pathol. 2003 May;119(5):672-80 [12760285.001]

[Cites] Blood. 2003 Dec 1;102(12):3880-9 [12920034.001]

[Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]

[Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]

[Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]

[Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]

[Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]

[Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]

[Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]

[Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]

[Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]

[Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]

[Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]

[Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]

[Cites] Blood. 2007 Feb 15;109(4):1387-94 [17082323.001]

[Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]

[Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]

[Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]

(PMID = 18483374.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib

[Other-IDs] NLM/ NIHMS281726; NLM/ PMC3074480

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia.

Here we report the case of a 43-year-old Japanese woman with acute myelogenous leukemia who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).

The patient did not achieve remission despite intensive chemotherapy, and subsequently underwent UCBT with a standard conditioning regimen.

[MeSH-major] Bacteremia / microbiology. Cord Blood Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Pulmonary / microbiology

[MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Fatal Outcome. Female. Humans

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - Tuberculosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19000153.001).

[ISSN] 1399-3062

[Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society

[ISO-abbreviation] Transpl Infect Dis

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antitubercular Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.

BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.

RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).

Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.

Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.

Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.

Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated.

Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.

The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).

CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Middle Aged. Vincristine / administration & dosage

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2008 American Cancer Society.

(PMID = 19090005.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide

[Other-IDs] NLM/ NIHMS629435; NLM/ PMC4180242

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.

Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone.

(iii) only the wide and rapid increment of BCR-ABL values was predictive of leukemia relapse.

[MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

[MeSH-minor] Adult. Aged. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Remission Induction

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16154854.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Comparative Study; Letter

[Publication-country] Italy

[Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

BACKGROUND: : Acute kidney injury (AKIis a common complication in the treatment of patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), but, to the authors' knowledge, its clinical relevance has not been detailed to date.

The objective of the current study was to identify the incidence, predictors, and outcome for AKI in patients with AML and HR-MDS.

METHODS: : Data were analyzed from 537 patients with AML or HR-MDS undergoing induction chemotherapy from 1999 to 2007.

Significant independent risk factors for AKI included the following: age >/=55 years (odds ratio [OR], 1.8), mechanical ventilation (OR, 16), use of vancomycin (OR, 2.3), diuretics (OR, 3.0), amphotericin B lipid formulation (OR, 2.7), vasopressors (OR, 4.9), leukopenia (OR, 1.9), hypoalbuminemia (OR, 1.4), and use of non-fludarabine-based chemotherapy (OR, 2.7).

The 8-week mortality rates were 3.8%, 13.6%, 19.6%, and 61.7% for the non-RIFLE, Risk, Injury, and Failure categories, respectively.

Survival of patients who achieved complete remission was favorable, regardless of degree of AKI.

CONCLUSIONS: : The RIFLE classification for AKI appears to have prognostic utility in predicting mortality in patients with AML or HR-MDS.

[MeSH-major] Acute Kidney Injury / epidemiology. Leukemia, Myeloid, Acute / complications. Myelodysplastic Syndromes / complications

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Kidney Function Tests / methods. Male. Middle Aged. Prognosis. Risk Factors

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Infect Dis. 2009 Aug 15;49(4):507-14 [19586413.001]

[Cites] Microvasc Res. 2009 Jan;77(1):8-12 [18929580.001]

[Cites] Nephrol Dial Transplant. 2004 Jul;19(7):1921-2 [15199201.001]

[Cites] Crit Care. 2004 Aug;8(4):R204-12 [15312219.001]

[Cites] South Med J. 1978 Apr;71(4):382-5 [635612.001]

[Cites] Cancer. 1985 Jan 1;55(1):18-25 [3855265.001]

[Cites] Chest. 1987 Aug;92(2):303-9 [3301221.001]

[Cites] Br J Haematol. 1988 Jun;69(2):247-52 [3291931.001]

[Cites] Intensive Care Med. 1990;16(5):291-7 [2212252.001]

[Cites] Crit Care Med. 1991 Mar;19(3):346-51 [1999095.001]

[Cites] Eur J Haematol. 1991 Aug;47(2):119-22 [1889480.001]

[Cites] Haematologica. 1998 May;83(5):416-21 [9658725.001]

[Cites] Nephrol Dial Transplant. 2005 Mar;20(3):552-8 [15671075.001]

[Cites] Chest. 2005 Nov;128(5):3098-108 [16304249.001]

[Cites] Crit Care Med. 2006 Feb;34(2):344-53 [16424713.001]

[Cites] Ann Thorac Surg. 2006 Feb;81(2):542-6 [16427848.001]

[Cites] Clin Nephrol. 2006 Feb;65(2):103-12 [16509459.001]

[Cites] N Engl J Med. 2006 Jun 15;354(24):2564-75 [16714767.001]

[Cites] Pediatr Nephrol. 2006 Aug;21(8):1194-6 [16721580.001]

[Cites] Bone Marrow Transplant. 2006 Sep;38(5):395 [16915229.001]

[Cites] Am J Transplant. 2007 Jan;7(1):168-76 [17109735.001]

[Cites] Am J Kidney Dis. 2007 Apr;49(4):517-23 [17386319.001]

[Cites] Clin Infect Dis. 2007 Jun 15;44(12):1536-42 [17516395.001]

[Cites] Clin Ther. 2007 Jun;29(6):1107-15 [17692725.001]

[Cites] Crit Care Med. 2007 Aug;35(8):1837-43; quiz 1852 [17581483.001]

[Cites] Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6 [18227177.001]

[Cites] Crit Care. 2008;12(3):R74 [18533029.001]

[Cites] Kidney Int. 2003 Feb;63(2):600-6 [12631124.001]

(PMID = 20564156.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Other-IDs] NLM/ NIHMS628065; NLM/ PMC4181579

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended therapy for patients with relapsed acute myelogenous leukemia (AML), despite little evidence showing a survival benefit in patients who undergo HSCT versus chemotherapy alone.

Because a prospective randomized trial addressing this issue is unlikely, we retrospectively reviewed all patients receiving initial salvage therapy for AML at M.D.

Anderson Cancer Center between 1995 and 2004, focusing on patients undergoing HSCT or chemotherapy without HSCT as second salvage after first salvage failed to produce complete remission (CR) (group A) and patients in first salvage-induced CR (group B).

[MeSH-major] Hematopoietic Stem Cell Transplantation / statistics & numerical data. Leukemia, Myeloid, Acute / surgery. Salvage Therapy / statistics & numerical data

[MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cytarabine / administration & dosage. Humans. Kaplan-Meier Estimate. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Transplantation Conditioning / statistics & numerical data. Transplantation, Homologous / statistics & numerical data. Whole-Body Irradiation / adverse effects. Whole-Body Irradiation / utilization

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 2000 Mar;14(3):476-9 [10720145.001]

[Cites] Bone Marrow Transplant. 2000 Dec;26(11):1157-63 [11149725.001]

[Cites] Blood. 2004 Aug 1;104(3):865-72 [15090449.001]

[Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]

[Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]

[Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]

[Cites] Cancer. 2007 Dec 15;110(12):2756-60 [17948909.001]

[Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9 [18275894.001]

[Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14 [15682071.001]

(PMID = 19822303.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA055164; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / T32 CA009666

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine

[Other-IDs] NLM/ NIHMS588413; NLM/ PMC4067765

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): a case study and review of the literature.

Subsequent histopathology disclosed sheets of mononuclear cells in the orbital mass, and immunohistochemical stains demonstrated positive results for myeloperoxidase and CD43, which supported the diagnosis of granulocytic sarcoma (GS).

The patient was diagnosed with acute myelogenous leukemia with t(8;21) preceded by orbital GS.

Our case is the first report of preceding orbital GS in an adult patient with a complex karyotype including t(8;21).

[MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / genetics. Orbital Neoplasms / pathology. Sarcoma, Myeloid / pathology. Translocation, Genetic

[MeSH-minor] Adult. Chromosome Banding. Follow-Up Studies. Humans. Immunohistochemistry. Karyotyping. Male. Remission Induction. Time Factors

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Cancer Genet Cytogenet. 2008 Nov;187(1):59

(PMID = 18656695.001).

[ISSN] 1873-4456

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 22

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

We hypothesized that comprehensive profiling of C&Ckine expression in leukemia would provide greater insight compared with individual analyses.

We used multiplex array technology to simultaneously measure the level of 27 C&Ckines in serum from 176 acute myelogenous leukemia (AML) and 114 myelodysplastic syndrome (MDS) patients and 19 normal controls.

C&Ckine levels in AML and MDS differed significantly from normal controls (5 higher, 13 lower) but were similar to each other for 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in AML and vascular endothelial growth factor A higher in MDS.

Levels did not correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytognetic abnormalities in AML.

In newly diagnosed AML, 8 C&Ckine signatures, distinct from the normal control signature, were observed.

These signatures had prognostic impact, affecting remission, primary resistance, relapse rates, and overall survival, individually (P = .003) and in multivariable analysis (P = .004).

These patterns suggest specific therapeutic interventions to investigate in subsets of AML patients.

In conclusion, C&Ckine expression in AML and MDS differs from normal, is similar with one another, and forms recurrent patterns of expression with prognostic relevance.

[MeSH-major] Chemokines / blood. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / diagnosis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Multivariate Analysis. Principal Component Analysis. Prognosis. Survival Analysis. Treatment Outcome. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 2002 Nov 1;95(9):1923-30 [12404286.001]

[Cites] Acta Haematol. 1996;96(3):155-61 [8876613.001]

[Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9 [12522051.001]

[Cites] Leukemia. 2003 Apr;17(4):716-30 [12682629.001]

[Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]

[Cites] Clin Immunol. 2004 Mar;110(3):206-21 [15047199.001]

[Cites] Best Pract Res Clin Haematol. 2004 Dec;17(4):653-61 [15494301.001]

[Cites] Blood. 1987 Apr;69(4):1161-6 [3103713.001]

[Cites] J Clin Invest. 1991 Mar;87(3):838-41 [1705566.001]

[Cites] Blood. 1992 Apr 15;79(8):1938-45 [1373331.001]

[Cites] Blood Rev. 1992 Sep;6(3):149-56 [1422283.001]

[Cites] Blood. 1993 Jan 15;81(2):281-92 [8422455.001]

[Cites] Leukemia. 1997 Dec;11(12):2049-54 [9447819.001]

[Cites] Br J Haematol. 1998 Sep;102(4):1025-34 [9734654.001]

[Cites] Cytokines Cell Mol Ther. 1998 Sep;4(3):187-98 [9825844.001]

[Cites] J Biopharm Stat. 2005;15(3):437-63 [15920890.001]

[Cites] Leuk Lymphoma. 2005 Jun;46(6):885-91 [16019534.001]

[Cites] Br J Haematol. 2005 Sep;130(5):709-15 [16115126.001]

[Cites] Cancer Treat Res. 2005;126:103-27 [16209064.001]

[Cites] Exp Hematol. 2005 Oct;33(10):1109-17 [16219533.001]

[Cites] Eur J Haematol. 2005 Dec;75(6):485-91 [16313260.001]

[Cites] Ann Clin Lab Sci. 2006 Winter;36(1):7-15 [16501231.001]

[Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]

[Cites] Cancer Biomark. 2005;1(6):259-69 [17192050.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):102-7 [17220337.001]

[Cites] Haematologica. 2007 Mar;92(3):332-41 [17339182.001]

[Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]

[Cites] Oncogene. 2007 Oct 15;26(47):6724-37 [17934481.001]

[Cites] Oncogene. 2007 Oct 15;26(47):6738-49 [17934482.001]

[Cites] Blood. 2008 May 1;111(9):4788-96 [18252861.001]

[Cites] Blood. 2008 May 1;111(9):4797-808 [18270328.001]

[Cites] Cancer. 2008 Oct 1;113(7):1605-13 [18683214.001]

[Cites] Blood. 2009 Jan 1;113(1):154-64 [18840713.001]

[Cites] Leuk Res. 1996 Nov-Dec;20(11-12):891-900 [9009245.001]

[Cites] Br J Cancer. 1999 Dec;81(8):1398-401 [10604739.001]

[Cites] Oncogene. 2000 Feb 3;19(5):624-31 [10698507.001]

[Cites] Cytokine. 2000 Jun;12(6):699-707 [10843748.001]

[Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]

[Cites] Trends Immunol. 2002 Aug;23(8):403-8 [12133803.001]

[Cites] Oncology. 2002;63(1):64-9 [12187073.001]

[Cites] Leukemia. 1994 May;8(5):798-805 [8182937.001]

[Cites] Blood. 1995 Dec 15;86(12):4594-602 [8541550.001]

[Cites] Leukemia. 1996 Jun;10(6):925-31 [8667646.001]

[Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]

[Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]

(PMID = 20679526.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA108631; United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Chemokines

[Other-IDs] NLM/ PMC4081283

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

OBJECTIVES: Angiogenesis seems important for both leukemogenesis and chemosensitivity in acute myelogenous leukemia (AML).

We investigated the constitutive release of MMPs and TIMPs for a large group of consecutive AML patients.

METHODS: AML cells were cultured in vitro either alone or together with microvascular endothelial cells, and levels of MMPs and TIMPs were determined in culture supernatants.

RESULTS: AML cells showed constitutive release of several MMPs and TIMPs.

MMP-9 release was higher for AML cells with monocytic differentiation corresponding to the FAB-subtype M4/M5 AML; it was mainly released in its inactive form, but endogenously active MMP-9 could be detected even in the presence of the constitutively released TIMP-1/2.

Endothelial cells released relatively high levels of MMP-10, and these levels were further increased by coculture with AML cells.

Patients achieving complete hematological remission after only one induction cycle showed relatively low constitutive MMP-2 release.

CONCLUSION: We conclude that primary human AML cells show constitutive release of both MMPs and TIMPs, and this release may be important for leukemogenesis and possibly also for chemosensitivity.

[MeSH-major] Leukemia, Myeloid / pathology. Matrix Metalloproteinases / secretion. Neoplasm Proteins / secretion. Tissue Inhibitor of Metalloproteinases / secretion

[MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Angiopoietin-2 / pharmacology. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / pharmacology. Bortezomib. Cells, Cultured / cytology. Chemokines / secretion. Coculture Techniques. Culture Media, Serum-Free / pharmacology. Cytarabine / administration & dosage. Diterpenes / pharmacology. Endothelial Cells / cytology. Female. Humans. Imidazoles / pharmacology. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Quinoxalines / pharmacology. Receptor, TIE-2 / antagonists & inhibitors. Receptor, TIE-2 / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / secretion

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. BORTEZOMIB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19922462.001).

[ISSN] 1600-0609

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; 0 / Angiopoietin-2; 0 / Anthracyclines; 0 / Boronic Acids; 0 / Chemokines; 0 / Culture Media, Serum-Free; 0 / Diterpenes; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Quinoxalines; 0 / Recombinant Proteins; 0 / Tissue Inhibitor of Metalloproteinases; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.- / Matrix Metalloproteinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.

Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia.

Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome.

Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid / drug therapy

[MeSH-minor] Acute Disease. Adolescent. Adult. Animals. Antimetabolites, Antineoplastic / administration & dosage. Bone Marrow Diseases / chemically induced. Cell Cycle / drug effects. Child. Cytarabine / pharmacology. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Flavonoids / administration & dosage. Flavonoids / pharmacology. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Middle Aged. Piperidines / administration & dosage. Piperidines / pharmacology. Premedication. Prognosis. Rats. Remission Induction / methods. Retrospective Studies. Salvage Therapy. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17364988.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 45AD6X575G / alvocidib; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor

[Number-of-references] 127

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.

The purpose of this study was to investigate whether levels of hTERT mRNA, as determined by real-time RT-PCR, are associated with prognosis and clinical course in AML patients.

Fifty-four bone marrow specimens from 21 patients diagnosed with de-novo AML were included.

The expression rates of hTERT mRNA were significantly higher at diagnosis (73%) and during relapse (80%) than during remission (27%) (P<0.05).

The median RR for diagnosis or relapse was significantly higher than that for patients in remission (P<0.05).

Two patients who showed hTERT mRNA expression during remission (RR 3.14 and 7.15, respectively) relapsed after 1 month.

Among seven patients with high hTERT mRNA levels (RR>9.51), 4 failed to achieve complete remission (CR), whereas 4 of 5 patients without hTERT mRNA expression at diagnosis or during relapse achieved CR (P>0.05).

Among eight samples showing hTERT mRNA expression in remission (RR>0), 5 were obtained from patients who had received GCSF within 14 days.

The expression rate and level of hTERT mRNA during remission were significantly higher in patients who had previously received GSCF (56%, RR=0.15) than in other patients (15%, RR=0) (P<0.05).

Serial and quantitative analysis of hTERT mRNA may be a useful marker for prediction of prognosis and monitoring in AML patients.

[MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Leukemia, Myeloid, Acute / diagnosis. RNA, Messenger / analysis. Telomerase / analysis

[MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Cells / enzymology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2005 Wiley-Liss, Inc.

(PMID = 16044449.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML).

RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML.

There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus.

AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells.

CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

[MeSH-major] Bone Marrow / pathology. Cytoplasm / chemistry. Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics

[MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal. Antineoplastic Agents / therapeutic use. Base Sequence. Cell Nucleolus. DNA Mutational Analysis. Humans. Karyotyping. Middle Aged. Remission Induction. Transfection. Translocation, Genetic

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetics Home Reference. consumer health - NPM1 gene.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

SciCrunch. OMIM: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 Massachusetts Medical Society.

[CommentIn] N Engl J Med. 2005 Jan 20;352(3):291-2 [15659732.001]

[CommentIn] N Engl J Med. 2005 Apr 28;352(17):1819-20; author reply 1819-20 [15858195.001]

[ErratumIn] N Engl J Med. 2005 Feb 17;352(7):740

(PMID = 15659725.001).

[ISSN] 1533-4406

[Journal-full-title] The New England journal of medicine

[ISO-abbreviation] N. Engl. J. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.

We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).

Interestingly, most of these cases had AML with AML1/ETO rearrangement.

To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).

The number of AML1/ETO+ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO- AML cells (2673 vs 522).

This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement.

We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.

[MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics

[MeSH-minor] Adolescent. Adult. Child. Female. Flow Cytometry. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Receptors, Granulocyte Colony-Stimulating Factor / analysis. Receptors, Granulocyte Colony-Stimulating Factor / genetics

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16791271.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.

Total body irradiation (TBI)-based conditioning regimens for pediatric patients with acute myelogenous leukemia (AML) beyond first complete remission (CR1) are controversial.

We retrospectively evaluated 151 pediatric patients with AML beyond CR1, comparing outcomes in 90 patients who received a TBI-based conditioning regimen and 61 patients who received a Bu-based conditioning regimen.

There were no differences between the 2 groups with respect to age, sex, duration of CR1, time from most recent remission to transplantation, or donor source.

Our study provides no evidence of an advantage to using TBI in children with AML beyond CR1.

[MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods

[MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Child. Child, Preschool. Cohort Studies. Cord Blood Stem Cell Transplantation / adverse effects. Cord Blood Stem Cell Transplantation / methods. Disease-Free Survival. Female. Humans. Infant. Male. Multivariate Analysis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Whole-Body Irradiation. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19896086.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined.

We screened 401 AML patients with normal karyotype treated within the German AML Cooperative Group Protocol 99 (AMLCG99) study for NPM1 mutations.

The NPM1-mutated group had a higher complete remission (CR) rate (70.5% vs 54.7%, P = .003), a trend to a longer overall survival (OS; median 1012 vs 549 days, P = .076), and significantly longer event-free survival (EFS; median 428 vs 336 days; P = .012).

The favorable impact of NPM1 mutations on OS and EFS clearly emerged in the large group (264 [66.8%] of 395 cases) of normal-karyotype AML without FLT3-LM.

In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype.

[MeSH-major] Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Survival Analysis

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16076867.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.

The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) is disease relapse or progression.

We analyzed the outcome of second HSCT for treatment of patients with relapsed, refractory AML/myelodysplastic syndrome (MDS) at our institution.

In all, 25 (35%) patients received salvage chemotherapy prior to the second transplant procedure and only two (3%) patients were in complete remission at the time of the second transplant.

A total of 20 patients (28%) had low leukemia burden as measured by the absence of peripheral blood blasts and <or=5% blasts in the bone marrow at the time of the second transplant.

Although, the overall median survival after the second transplant was 6 months, a subset of patients who had low leukemia burden at the time of the second transplant had a 5-year survival of 25 vs 12% in those with a high leukemia burden.

[MeSH-major] Leukemia, Myeloid, Acute / prevention & control. Salvage Therapy. Stem Cell Transplantation. Tumor Burden

[MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15937511.001).

[ISSN] 0268-3369

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].

OBJECTIVE: To analyse the outcome of newly diagnosed adult acute myeloid leukemia (AML) patients treated with HAA (homoharringtonine, cytarabine and aclarubicin) regimen and explore the efficacy and safety of this regimen.

The complete remission (CR) rate was observed.

For the AML-M5 and AML-M /M2 patients the CR rate was 74% and 87% and 3 year RFS of CR patients was 75% and 37%, respectively.

CONCLUSION: HAA regimen is a safe, efficacious, and well-tolerable induction therapy for newly diagnosed AML.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Aclarubicin / administration & dosage. Adolescent. Adult. Cytarabine / administration & dosage. Female. Harringtonines / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18512308.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine; 6FG8041S5B / homoharringtonine; 74KXF8I502 / Aclarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.

Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy.

If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.

Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks.

The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics.

In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group.

The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group.

Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST.

Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.

[MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods

[MeSH-minor] Adult. Aged. Cytogenetics. Disease-Free Survival. Female. Graft vs Host Disease / mortality. Humans. Karyotyping. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20087795.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia.

A 43-year-old man with acute myelogenous leukemia (AML) was found to be complicated with pulmonary alveolar proteinosis (PAP), which was confirmed by biochemical and histological findings.

After achievement of complete remission of AML, he underwent whole-lung lavages twice between intensive chemotherapies.

He has been in remission for 25 months after transplant with no recurrence of PAP.

[MeSH-major] Bronchoalveolar Lavage. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation. Pulmonary Alveolar Proteinosis / therapy

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Remission Induction / methods. Transplantation, Autologous

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2006 Wiley-Liss, Inc.

(PMID = 16432866.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].

A 42-year-old woman was admitted to our hospital with acute myelogenous leukemia.

After receiving one cycle of induction therapy, she achieved complete remission and blood group A antigen was proven on her red blood cells.

[MeSH-major] ABO Blood-Group System / immunology. Blood Grouping and Crossmatching. Leukemia, Myeloid, Acute / blood

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Remission Induction

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18277597.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / ABO Blood-Group System; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.

We analyzed the outcome of RIC HSCT in acute myelogenous leukemia (AML) patients over the age of 40 years.

Forty-three AML or high-risk myelodysplastic syndrome (MDS) patients were treated with a fludarabine and low-dose total-body irradiation (TBI)-based pretransplantation regimen.

All but 2 AML patients were in complete remission (CR) at the time of transplantation.

Sixty percent of patients developed acute graft-versus-host disease (aGVHD), which was grade II in 40% and grade III in 12%.

In conclusion, fludarabine plus low-dose TBI-based RIC HSCT is effective in AML patients over the age of 40 years without active disease at the time of transplant and is associated with low TRM.

[MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods

[MeSH-minor] Adult. Age Factors. Aged. Female. Graft Survival. Graft vs Host Disease. Humans. Male. Middle Aged. Myelodysplastic Syndromes. Opportunistic Infections. Survival Rate. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. FLUDARABINE .

Hazardous Substances Data Bank. VIDARABINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18215778.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.

Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation in chronic myelogenous leukemia compared to sibling donors.

We compared outcomes for 105 patients aged 16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected matching set of 105 HLA-matched sibling donor (MSD) transplants.

There were 18 good risk (complete remission [CR]1) and 87 poor risk (>CR1) recipients in both URD and sibling groups.

There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or above at 100 days.

Based on this data, URD allografts should be considered in AML patients without a matched sibling donor.

This study provides a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML.

[MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy

[MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Siblings. Transplantation, Homologous / adverse effects. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17448920.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].

OBJECTIVE: To report disease transformation in 3 imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia (Ph(+)CML) patients who achieved cytogenetic response.

Though under continuously imatinib treatment, they developed acute lymphoblastic leukemia, acute myelogenous leukemia and extramedullary blast crisis in the following 12, 6 and 0 months respectively.

CONCLUSION: Acute leukemia or extramedullary blast crisis with Ph(-) cells or dominant Ph(-) cells in bone marrow may occur in the patients with Ph(+)CML after imatinib therapy.

[MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

[MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Benzamides. Disease Progression. Female. Humans. Imatinib Mesylate. Karyotyping. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction

MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16378113.001).

[ISSN] 1671-167X

[Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[ISO-abbreviation] Beijing Da Xue Xue Bao

[Language] chi

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.

BACKGROUND: The T315I mutation of BCR/ABL gene is known to produce complete resistance of chronic myelogenous leukemia (CML) to all currently available BCR/ABL inhibitors.

Despite satisfactory hematological remission, he failed to achieve complete cytogenetic remission within the first year of treatment.

The course of transplantation was complicated by staphylococcal sepsis, grade I skin acute GvHD and limited chronic skin GVHD.

However, the goal of alloSCT was achieved and the patient remains in complete molecular remission at week +68 post-transplantation.

[MeSH-major] Genes, abl. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Mutation, Missense

[MeSH-minor] Adult. Amino Acid Substitution. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Humans. Leukemia, Myeloid, Accelerated Phase / drug therapy. Leukemia, Myeloid, Accelerated Phase / genetics. Leukemia, Myeloid, Accelerated Phase / therapy. Male. Protein Kinase Inhibitors / pharmacology. Remission Induction. Transplantation, Homologous

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20657522.001).

[ISSN] 2329-0358

[Journal-full-title] Annals of transplantation

[ISO-abbreviation] Ann. Transplant.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Poland

[Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Fusion Proteins, bcr-abl

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acute myelogenous leukemia with mediastinal and subcutaneous emphysema following chronic GVHD after allogeneic bone marrow transplantation].

A 38-year-old man was diagnosed as having acute myelogenous leukemia in December 2001.

He achieved a complete remission after undergoing three courses of induction chemotherapy.

[MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Leukemia, Myeloid, Acute / therapy. Mediastinal Emphysema / etiology. Subcutaneous Emphysema / etiology

[MeSH-minor] Adult. Chronic Disease. Disease Progression. Fatal Outcome. Humans. Lung Diseases, Interstitial / etiology. Male. Transplantation, Homologous

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - Emphysema.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16440761.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.

BACKGROUND: Most patients with acute myelogenous leukemia (AML) suffer from disordered hemostasis.

We have previously shown that annexin II (Ann II), a high-affinity co-receptor for plasminogen/tissue plasminogen activator, plays a central role in primary hyperfibrinolysis in patients with acute promyelocytic leukemia (APL).

The expression of Ann II in cells from patients with major subtypes of AML and the effect of arsenic trioxide (As2O3) on Ann II expression in AML cells were investigated to determine whether As2O3-mediated downregulation of Ann II could restore hemostatic stability.

Plasma samples were collected before and after treatment as well as after complete remission.

CONCLUSIONS: As2O3 may reduce hyperfibrinolysis in AML by downregulation of Ann II.

Furthermore, As2O3 affects more than one form of AML (APL, M4 and M5), suggesting its potential role in their management.

[MeSH-major] Annexin A2 / metabolism. Arsenicals / pharmacology. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Down-Regulation / drug effects. Leukemia, Promyelocytic, Acute / metabolism. Oxides / pharmacology

[MeSH-minor] Adult. Cell Survival / drug effects. Cells, Cultured. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19781379.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Annexin A2; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.

We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).

Nine patients had relapsed AML (ages, 18-59 years, n = 4 and > or = 60 years, n = 5).

There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).

Overall, 19 patients (61%) achieved complete remission (CR) and three had CR with incomplete platelet recovery.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Boronic Acids / administration & dosage. Bortezomib. Cohort Studies. Cytarabine / administration & dosage. Female. Gene Expression Profiling. Humans. Idarubicin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Oligonucleotide Array Sequence Analysis. Pyrazines / administration & dosage. Tissue Distribution. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18316568.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA066996

[Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features.

Thirty patients (67%) achieved complete remission (CR) and 4 (9%) died.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. Allopurinol .

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.

[Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]

[Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]

[Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]

[Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]

[Cites] Cell Death Differ. 2001 Jul;8(7):715-24 [11464216.001]

[Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]

[Cites] Genome Biol. 2001;2(10):RESEARCH0041 [11597333.001]

[Cites] Clin Cancer Res. 2002 Nov;8(11):3527-38 [12429644.001]

[Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]

[Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]

[Cites] Clin Cancer Res. 2003 Jan;9(1):307-15 [12538483.001]

[Cites] Cancer Res. 2003 Apr 15;63(8):1822-33 [12702569.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]

[Cites] Am J Med. 1969 Sep;47(3):351-66 [5258033.001]

[Cites] Ann Intern Med. 1975 Jan;82(1):54-7 [16553.001]

[Cites] Medicine (Baltimore). 1980 Nov;59(6):409-25 [7003298.001]

[Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]

[Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]

[Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]

[Cites] Cancer Res. 1996 Nov 1;56(21):4856-61 [8895733.001]

[Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]

[Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]

[Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]

[Cites] Mol Cancer Ther. 2006 Jan;5(1):138-48 [16432172.001]

[Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]

[Cites] Leuk Lymphoma. 2006 Apr;47(4):697-706 [16690529.001]

[Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]

[Cites] Blood. 2007 Mar 1;109(5):1810-6 [17095617.001]

[Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]

[Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73 [17671131.001]

[Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]

[Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]

[Cites] Blood. 2009 Apr 23;113(17):4052-62 [19144991.001]

[CommentIn] Leuk Res. 2010 Jul;34(7):856-7 [20378170.001]

(PMID = 19962759.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone

[Other-IDs] NLM/ NIHMS158765; NLM/ PMC2875369

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML).

We conducted an adaptively randomized study of a combination of azacitidine, a hypomethylating agent, and cytarabine in 34 patients with AML.

However, in this advanced AML population, it was difficult to deliver more than one cycle of therapy, and minimal anti-leukemia activity was seen in patients with relapsed/refractory disease.

Complete remission was achieved in 2 of 6 minimally pre-treated patients.

We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory AML.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]

[Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7512-23 [14576855.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]

[Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]

[Cites] Biochim Biophys Acta. 1965 Nov 8;108(3):516-8 [5867538.001]

[Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]

[Cites] Cancer Res. 1974 Oct;34(10):2482-8 [4137739.001]

[Cites] Biochemistry. 1975 Jan 28;14(2):316-26 [47243.001]

[Cites] Oncology. 1974;30(5):405-22 [4142650.001]

[Cites] Cancer Res. 1975 Oct;35(10):2853-7 [50882.001]

[Cites] Cancer Res. 1976 Mar;36(3):1114-20 [56229.001]

[Cites] Cancer Res. 1978 Aug;38(8):2458-66 [78761.001]

[Cites] Cell. 1980 May;20(1):85-93 [6156004.001]

[Cites] Cancer Res. 1980 Nov;40(11):4000-6 [6162541.001]

[Cites] Science. 1981 Jan 23;211(4480):393-6 [6164095.001]

[Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]

[Cites] Cancer Res. 1984 Nov;44(11):5029-37 [6091869.001]

[Cites] Adv Enzyme Regul. 1985;24:335-54 [2424284.001]

[Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):257-61 [3035720.001]

[Cites] Cancer Chemother Pharmacol. 1989;24(4):203-10 [2473850.001]

[Cites] Blood. 1997 Jul 1;90(1):346-53 [9207471.001]

[Cites] Br J Haematol. 1998 Dec;103(4):1096-103 [9886326.001]

[Cites] Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78 [15533764.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3895-903 [16921040.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]

[Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]

[Cites] Clin Cancer Res. 2007 Jul 15;13(14):4225-32 [17634552.001]

[Cites] Biometrics. 2007 Jun;63(2):429-36 [17688495.001]

[Cites] Blood. 2008 Aug 15;112(4):1366-73 [18523155.001]

[Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]

[Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]

(PMID = 20017599.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA100632-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632-04; United States / NCI NIH HHS / CA / P50 CA100632-079004; United States / NCI NIH HHS / CA / CA100632-07S1; United States / NCI NIH HHS / CA / P50 CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / P50 CA100632-069004; United States / NCI NIH HHS / CA / CA100632-04; United States / NCI NIH HHS / CA / CA100632-070006; United States / NCI NIH HHS / CA / CA100632-070001; United States / NCI NIH HHS / CA / CA100632-03; None / None / / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-03; United States / NCI NIH HHS / CA / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-069004; United States / NCI NIH HHS / CA / P50 CA100632-070001; United States / NCI NIH HHS / CA / CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632-010007; United States / NCI NIH HHS / CA / P50 CA100632-070006; None / None / / P50 CA100632-010007; United States / NCI NIH HHS / CA / CA100632; United States / NCI NIH HHS / CA / CA100632-079004; United States / NCI NIH HHS / CA / P50 CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-07; United States / NCI NIH HHS / CA / P50 CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-05; United States / NCI NIH HHS / CA / CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-010001; United States / NCI NIH HHS / CA / P50 CA100632-07S1; United States / NCI NIH HHS / CA / CA100632-07; United States / NCI NIH HHS / CA / CA100632-010001

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 04079A1RDZ / Cytarabine; M801H13NRU / Azacitidine

[Other-IDs] NLM/ NIHMS200831; NLM/ PMC2876330

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

To investigate the efficacy of using recombinant human interleukin 11 (rhIL-11) to reduce the need for platelet transfusions, we performed a randomized, double-blind phase II/III study with 110 acute myelogenous leukemia (AML) patients in the first complete remission.

These results show that rhIL-11 does not reduce the platelet transfusion requirement in AML patients, but the retrospective analysis confirms the previous finding that rhIL-11 reduces infection in patients undergoing chemotherapy.

[MeSH-major] Interleukin-11 / administration & dosage. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Double-Blind Method. Female. Humans. Infection / drug therapy. Infection / etiology. Male. Middle Aged. Placebos. Platelet Transfusion. Recombinant Proteins / therapeutic use. Retrospective Studies. Stomatitis / drug therapy. Stomatitis / etiology

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17261503.001).

[ISSN] 0925-5710

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Interleukin-11; 0 / Placebos; 0 / Recombinant Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.

Mutations of the nucleophosmin gene (NPM1), in the absence of concurrent FLT3-internal tandem duplication (FLT3-ITD) have impressive prognostic value in patients with acute myelogenous leukemia (AML), carrying normal karyotype (NK).

In this study we describe treatment results from a series of 19 patients with NPM+/FLT3- autografted in first complete remission (CR) after conditioning with a regimen, named BuI, based on high-dose continuous infusion of idarubicin and Busulfan.

Ninety-nine consecutive patients (median age of 54 years) with NK AML autografted in first CR were analyzed.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Mutation. Nuclear Proteins / genetics. Stem Cell Transplantation. Transplantation Conditioning / methods

[MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prognosis. Treatment Outcome. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20172040.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience.

We analyze the prevalence and clinical features of a group of patients with t(8;21) (q22;q22) acute myeloblastic leukemia, identified in a single institution in México over a 10-year period.

According to the French-American-British (FAB) morphological classification of leukemia, the morphology was M2 in four cases, M4 in three cases, M3 in one case and M0 in one.

In addition to the myeloid markers, lymphoid markers were identified in 6 patients.

Patients were induced to remission with combined chemotherapy and three subsequently underwent bone marrow transplantation (BMT).

In this single-center experience in México, we found that the t(8;21) (q22;q22) variant of leukemia was more frequent than in Caucasian populations, that the co-expression of lymphoid markers in the blast cells is very frequent and that this malignancy is associated with a relatively good prognosis.

[MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid / genetics. Oncogene Proteins, Fusion / genetics. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Translocation, Genetic

[MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Prevalence. Prospective Studies. Remission Induction. Salvage Therapy. Transplantation, Autologous / statistics & numerical data. Transplantation, Homologous / statistics & numerical data. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17178661.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 80168379AG / Doxorubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.

In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.

Complete cytogenetic and morphologic remission of AML was evident on follow-up marrow aspirate and biopsy specimens from all patients.

In two of the four study patients, the disease remains in complete remission and the patients have an excellent quality of life (Eastern Cooperative Oncology Group performance status 0; no medications) and no organ toxicity more than 2 years and more than 4 years, respectively, after their blood and bone marrow transplantations.

Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow.

[MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use

[MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Bone Marrow / radiation effects. Dose-Response Relationship, Radiation. Humans. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Quality of Life. Remission Induction / methods. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16966270.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.

A myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, and 400 cGy total-body irradiation was given before allogeneic stem cell transplantation (SCT) to 64 adults with acute leukemia in first and second remission.

For 31 matched related (MRD) and 33 alternate donor (AD) SCT the incidence of acute GVHD grade II-IV was 11% +/- 6% versus 35% +/- 9% (P = .047), acute GVHD grade III-IV was 0% versus 10% +/- 6% (P = .09), and chronic GVHD was 40% +/- 9% versus 66% +/- 9% (P = NS), respectively.

Projected disease-free (DFS) and overall survival (OS) at 3 years for acute myelogenous leukemia (AML) (n = 36) are the same at 83% +/- 6%, and for acute lymphoblastic leukemia (ALL) (n = 28) are 65% +/- 10% and 78% +/- 8%, respectively.

[MeSH-major] Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning

[MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antilymphocyte Serum. Antineoplastic Agents / administration & dosage. Busulfan / administration & dosage. Cyclosporine / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Myeloablative Agonists / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUDARABINE .

Hazardous Substances Data Bank. BUSULFAN .

Hazardous Substances Data Bank. VIDARABINE .

Hazardous Substances Data Bank. METHOTREXATE .

Hazardous Substances Data Bank. CYCLOSPORIN A .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17580259.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 0 / thymoglobulin; 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.

Twenty-seven acute myelogenous leukemia patients in their first complete remission received 76 cycles of HiDAC (median cycle: n = 3).

[MeSH-major] Cytarabine / therapeutic use. Leukemia, Myeloid, Acute / complications. Mycoses / epidemiology

[MeSH-minor] Adult. Antifungal Agents / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Continental Population Groups. Dose-Response Relationship, Drug. Female. Fluconazole / therapeutic use. Humans. Male. Middle Aged. Neutropenia / epidemiology. Reproducibility of Results. Risk Assessment

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Fungal Infections.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 S. Karger AG, Basel.

(PMID = 21071929.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antifungal Agents; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 8VZV102JFY / Fluconazole

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

One hundred twelve acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT.

Most patients (73%) were not in remission.

The complete remission (CR) rate was 82%.

In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV acute GVHD.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods

[MeSH-minor] Adult. Aged. Disease Progression. Drug Therapy, Combination. Female. Humans. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Middle Aged. Risk Factors. Survivors. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. MELPHALAN .

Hazardous Substances Data Bank. FLUDARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2001 Feb 1;97(3):631-7 [11157478.001]

[Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]

[Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]

[Cites] Blood. 2001 Oct 15;98(8):2326-31 [11588026.001]

[Cites] Br J Haematol. 2002 Dec;119(4):1115-24 [12472596.001]

[Cites] Blood. 2004 Jan 15;103(2):479-85 [14512295.001]

[Cites] Blood. 2004 Aug 1;104(3):857-64 [15073038.001]

[Cites] Blood. 2004 Aug 1;104(3):865-72 [15090449.001]

[Cites] Am J Hum Genet. 1987 Nov;41(5):867-81 [2890295.001]

[Cites] Blood. 1992 Jan 15;79(2):473-6 [1370388.001]

[Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]

[Cites] Br J Haematol. 1996 Apr;93(1):89-95 [8611481.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]

[Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]

[Cites] Blood. 1997 Jun 15;89(12):4531-6 [9192777.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]

[Cites] Leuk Res. 1998 May;22 Suppl 1:S3-6 [9734692.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1993-2003 [15774790.001]

[Cites] Blood. 2005 Nov 1;106(9):3314-21 [16020510.001]

[Cites] Br J Haematol. 2000 Oct;111(1):18-29 [11091179.001]

[Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]

(PMID = 17382251.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA055164

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan

[Other-IDs] NLM/ NIHMS588352; NLM/ PMC4080636

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].

Fifty-seven patients with acute myelogenous leukemia (AML) received the following treatment in our hospital between May 1992 and April 2005.

Group A: combination of enocitabine, daunorubicin, 6-mercaptopurine riboside and prednisolone (BHAC-DMP) for remission induction, BHAC-DMP or idarubicin (IDR)+cytarabine (Ara-C) for first consolidation, combination of prednisolone, Ara-C, mitoxantrone and etoposide (PAME) for second consolidation, and PAME for late intensification; Group B: IDR+Ara-C for remission induction, PAME for first consolidation, and high-dose Ara-C+mitoxantrone for second consolidation; Group C (acute promyelocytic leukemia, APL) : all-trans retinoic acid (ATRA) for remission induction, BHAC-DMP or IDR+Ara-C for first consolidation, and PAME for second consolidation.

The complete remission (CR) rate was 77% in Group A, 76% in Group B, and 71% in Group C.

A short duration treatment with intensive consolidation therapy was effective for patients with AML and improved their quality of life (QOL).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Aged. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Daunorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Evidence-Based Medicine. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. MERCAPTOPURINE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18030012.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin; BHAC-DMPV protocol; PAME protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors.

In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML.

Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%.

Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]

[Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]

[Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]

[Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]

[Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]

[Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]

[Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]

[Cites] J Clin Oncol. 1989 Sep;7(9):1268-74 [2475589.001]

[Cites] Cancer Res. 1992 May 15;52(10):2847-53 [1581898.001]

[Cites] Cancer Res. 1994 Jun 15;54(12):3229-32 [8205544.001]

[Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]

[Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]

[Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]

[Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2318-25 [10873082.001]

[Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]

[Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]

[Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]

[Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]

[Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]

[Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]

[Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]

[Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]

[Cites] Cancer Res. 2002 Jan 15;62(2):450-8 [11809695.001]

[Cites] Blood. 2002 Jul 1;100(1):29-35 [12070004.001]

[Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]

[Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]

[Cites] Cancer Res. 1995 Aug 1;55(15):3295-304 [7614464.001]

[Cites] Cancer Res. 1995 Nov 15;55(22):5302-9 [7585592.001]

[Cites] Cancer Res. 1997 Feb 15;57(4):708-13 [9044849.001]

[Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]

[Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]

[Cites] Blood. 1997 Oct 15;90(8):2969-77 [9376577.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]

[Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]

[Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1439-45 [9779989.001]

[Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]

[Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]

[Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]

[Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]

[Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]

(PMID = 17082323.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase

[Other-IDs] NLM/ PMC1794070